Obesity is a main health problem, that affects people all over the world. According to recent articles, obese patients should be denied any therapy to aim improving ovulation rates and achieving pregnancy until their BMI is reduced. We believe that this approach does not solve the issue, but rather exacerbates the maternal and perinatal complications linked to fertility clinics. Obesity independent of polycystic ovary syndrome (PCOS) is related with anovulation, and a weight loss alone is an effective treatment for inducing ovulation in both obese women with or not PCOS. As a result, weight-loss lifestyle programs should be considered an ovulation induction therapy, with due consideration for a possible pregnancy in an obese woman. Obesity has been linked to menstrual irregularities and infertility, Despite the fact that a critical mass of adipose tissue is needed for development female reproductive function. The severity of fat tissue distribution and obesity are important factors that affect the female reproductive system. The mechanisms of pathogenetic that link them aren't well understood. Insulin resistance and hyperinsulinemia are common in obese, especially those women with upper obesity of body, as are hyperandrogenemia, increased peripheral aromatization of androgens to oestrogens, altered secretion of gonadotrophin, and reduced (SHBG), decreased growth hormone (GH) , insulin like growth factor binding proteins (IGFBPs), elevated level of leptin and changed neuroregulation of the hypothalamic‐pituitary‐gonadal axis.

Toxoplasmosis is well known as a cause of infection in pregnant women. Although many serological methods are available, diagnosis of early Toxoplasmosis may be extremely difficult. Toxoplasmosis is typically diagnosed during pregnancy via testing of maternal serum for IgM and IgG anti-Toxoplasma antibodies. Toxoplasmosis is normally asymptomatic, but it can have serious effects in immune-deficient individuals. Because avidity increases over time during infection, determining specific IgG avidity allows for more precise dating. Long-term IgM persistence makes it difficult to distinguish between acute and chronic infection. Seventy-six women were tested for VIDAS lgM, lgG antibodies, and VIDAS toxo-IgG avidity during the first 16 weeks of pregnancy. Low avidity antibodies were found in two (33.3%) of the six IgM-positive sera and four (11.11%) of the IgG-positive sera. Low avidity was noticed in 2 (3.27%) of the 61 sera that were negative for IgM. The low avidity indicates a recent infection, whereas high avidity in 4 (50%) of the 6 positive IgM and 24 (74.74%) of the 33 positive IgG indicates a long-ago infection. These conclusions emphasise the importance of using “VIDAS IgG avidity” in conjunction with the VIDAS IgM and IgG assays to offer to prove the presence of acute infection from a single serum sample for pregnant women.

Around 80% of the hyperthyroidism cases of women of childbearing age are inflammatory due to Graves' disease. Production and manifestation of other than gestational and early-onset diabetes may be linked to the hormonal modifications in the maternal immune system during birth. Therefore, in addition to the hormonal influences, the pregnancy test will be affected by various anatomical modifications or alterations seen in the body during pregnancy. For the health of a woman and the start of her pregnancy, thyroid hormones are very significant. These hormones are critical in early development and play a vital role in continuing the fetus's growth since conception. Women with untreated or inadequately controlled hyperthyroidism are at risk of giving birth problems. Future diseases, particularly those with IUGRTH producing so many fetuses. The treatment of hyperthyroid pregnant people is so tricky, and medical staff involvement is needed to ensure that it's monitored and treated in various ways. Pregnant women are prescribed antithyroid medications, and it is the medication of preference for most pregnant women (ATDs). Although both of these medications are transmitted to the fetus by the mother's bloodstream, they are significantly efficient in the treatment of maternal hyperthyroidism. Still, they need caution throughout the second half of pregnancy because of the possibility of fetopathy. Except in the first trimesters from weeks 6 to 10 weeks, the most prevalent adverse effect is abnormalities in the fetal; even with that as a caveat, the incidence of birth defects is high during the first trimester with the help of ATDs. The treatment of hyperthyroidism during pregnancy goes into four issues that are currently of major importance to obstetricians: its aetiology, disease occurrence, proper detection, under treatment, complications, and actual or a missed diagnosis and intervention, and finally, the method of dealing with the problem.